GlassScriptPhysician profile
Sai Sun Ho
NPI 1710952957
$30,671.60
in general payments reported to CMS, 2019-2025
39 companies · $2,641 in 2025
The $2,641 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,679 · 2020: $5,354 · 2021: $4,729 · 2022: $4,323 · 2023: $4,149 · 2024: $3,797 · 2025: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,579.94 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,884.32 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Janssen Pharmaceuticals, INC | $3,683.10 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $3,034.56 | 2019-2025 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,025.01 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Glaxosmithkline, LLC. | $2,445.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $2,436.94 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Novo Nordisk INC | $2,403.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,336.75 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $855.73 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $652.70 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $651.39 | 2019-2024 | Linzess |
| Amgen INC. | $579.20 | 2019-2025 | Otezla, Krystexxa, Tavneos |
| Pfizer INC. | $568.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $385.65 | 2019-2023 | Eliquis |
| Astellas Pharma US INC | $354.87 | 2020-2025 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sai Sun Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.